Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Before Micatrio, Patient Must Take 3 Contained Compounds for at Least 8 Weeks: MHLW
November 29, 2016
- Japan Ophthalmologists Association Calls for Reductions in NHI Prices of High-Cost Drugs
November 29, 2016
- LDP Study Group Kicks Off to Put Brakes on Hasty Push for Biosimilars
November 28, 2016
- Eltrombopag, Nusinersen Designated as Orphan Drugs
November 28, 2016
- MHLW Advisory Panel OKs Biogen’s Tecfidera, Other Drugs
November 28, 2016
- Annual Price Revision Push Gaining Momentum; PM Wants Pricing Revamp Policy by Year-End
November 28, 2016
- MHLW Panel OKs Celgene’s Apremilast, 2 Other NMEs
November 25, 2016
- MHLW Looks to Extend MID-NET to Cover Clinic Data: Bureau Chief
November 25, 2016
- More Patient Participation Needed to Promote Drug Development, Safety Measures: MHLW Official
November 25, 2016
- Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
November 25, 2016
- Polaprezinc Ordered to Add Copper Deficiency in ADR List
November 24, 2016
- LDP’s Health Committee Demands Enhanced R&D Tax Break as Key Priority
November 24, 2016
- MHLW OKs Janssen’s HIV Combo Pill Prezcobix
November 24, 2016
- AMED to Allocate 240 Million Yen for R&D of Innovative Cancer Treatments, Including CAR-T Cell Therapy
November 24, 2016
- MHLW to Announce Opdivo’s New Prices on Nov. 24
November 24, 2016
- MHLW to Revise Rules on Development Requests for Unapproved Drugs
November 22, 2016
- Council OKs Public Knowledge-Based Application for Tamiflu’s New Pediatric Dosage
November 22, 2016
- MHLW to Set Up Quake-Resistant Warehouse to Stockpile Vaccines Using Supplementary Budget for FY2016
November 21, 2016
- MHLW to Kick Off Discussions for Major Drug Pricing Overhaul by Year-End: Bureau Chief
November 18, 2016
- MOF Panel Budget Recommendation Calls for Curbing Drug Costs
November 18, 2016
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…